News and Announcements
Newground Capital Increases Deal Pipeline to $650m+ & Provides $138m Partnership Capital to Australian East Coast Projects
- Published July 12, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Newground Capital is a boutique real estate investment manager, combining local knowledge and expertise in the Australian Real Estate market with international investment capability. Over the past 12 months, we have been focused on expanding our platform in Australia while also forging stronger relationships with institutional investors and family offices across Asia. We are pleased to highlight some of our achievements from 2017:
- During FY17 Newground provided partnership capital to approx. $138m in projects on Australia’s East Coast;
- Deal pipeline has significantly increased to $650m+ due to expanded deal origination network;
- Expanded execution capability to include Melbourne with the recent appointment of new investment team in addition to the offices in Sydney & Brisbane;
- Appointment of ex ANZ Senior Executive Mr Stephen Hall to the board as Executive Director, Head of Credit;
- Through our active presence in Hong Kong and Singapore, we continued to increase mandates with Asia based family office & institutional investors to deploy capital in the Australian CRE debt market.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
